A thorough understanding of the precise relationship between KDM1A and BMP‐2 will allow us to develop effective strategies for targeted local delivery of KDM1A‐based agents with therapeutic potential against neointimal hyperplasia and other vascular disorders. The gene discussed is BMP2; the disease is vascular disorder.